SCICLONE PHARMACEUTICALS INC's ticker is SCLN and the CUSIP is 80862K104. A total of 134 filers reported holding SCICLONE PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $970,000 | -7.5% | 86,607 | -9.2% | 0.00% | -50.0% |
| Q2 2017 | $1,049,000 | +11.6% | 95,337 | -0.6% | 0.00% | +100.0% |
| Q1 2017 | $940,000 | -24.5% | 95,937 | -16.8% | 0.00% | -50.0% |
| Q4 2016 | $1,245,000 | -19.6% | 115,297 | -23.6% | 0.00% | -33.3% |
| Q3 2016 | $1,548,000 | -36.0% | 150,937 | -18.6% | 0.00% | -25.0% |
| Q2 2016 | $2,420,000 | +196.9% | 185,317 | +150.4% | 0.00% | +300.0% |
| Q1 2016 | $815,000 | +2.9% | 74,017 | -14.0% | 0.00% | 0.0% |
| Q4 2015 | $792,000 | +58.1% | 86,037 | +19.1% | 0.00% | 0.0% |
| Q3 2015 | $501,000 | -28.8% | 72,237 | +0.7% | 0.00% | 0.0% |
| Q2 2015 | $704,000 | +1054.1% | 71,737 | +522.1% | 0.00% | – |
| Q2 2014 | $61,000 | -40.8% | 11,532 | -49.1% | 0.00% | – |
| Q1 2014 | $103,000 | -53.6% | 22,637 | -48.7% | 0.00% | – |
| Q4 2013 | $222,000 | -30.0% | 44,137 | -29.3% | 0.00% | -100.0% |
| Q3 2013 | $317,000 | +1.9% | 62,437 | -0.3% | 0.00% | 0.0% |
| Q2 2013 | $311,000 | – | 62,637 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athos Capital Ltd | 284,200 | $3,126,000 | 1.80% |
| Nine Chapters Capital Management LLC | 13,600 | $150,000 | 1.42% |
| Stonepine Capital Management, LLC | 216,307 | $2,379,000 | 1.28% |
| GLG Partners LP | 1,588,897 | $17,478,000 | 0.97% |
| MENTA CAPITAL LLC | 431,996 | $4,752,000 | 0.56% |
| Sapphire Star Partners LP | 24,834 | $273,000 | 0.34% |
| Yakira Capital Management, Inc. | 85,500 | $941,000 | 0.28% |
| TFS CAPITAL LLC | 55,104 | $606,000 | 0.24% |
| BRANT POINT INVESTMENT MANAGEMENT LLC | 100,000 | $1,100,000 | 0.13% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 102,261 | $1,125,000 | 0.12% |